MK-0941, a novel glucokinase activator (GKA), lowers HbA1c in type 2 diabetes (T2DM) but lacks glycaemic durability

被引：0
|
作者：
Meininger, G. E. [1 ]
Shentu, Y. [1 ]
Chen, Y. [1 ]
Yu, Q. [1 ]
Sheng, D. [1 ]
Musser, B. J. [1 ]
Alba, M. [1 ]
Zhang, B. B. [1 ]
Migoya, E. M. [1 ]
Ehrhart, J. [1 ]
Kaufman, K. D. [1 ]
Goldstein, B. J. [1 ]
机构：
[1] Merck, Rahway, NJ USA
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
242
引用
收藏
页码：S107 / S107
页数：1
相关论文
共 50 条
  • [31] TTP399, a Liver-Selective Glucose Kinase Activator (GKA), Lowers Glucose and Does NOT Increase Lipids in Subjects with Type 2 Diabetes Mellitus (T2DM)
    Valcarce, Carmen
    Grimes, Imogene
    Gustavson, Stephanie
    Burstein, Aaron
    Mjalli, Adnan
    [J]. DIABETES, 2014, 63 : A32 - A32
  • [32] Five-Year Population Level Trajectory of HbA1c (AIC) and its Association With Mortality in Patients With Type 2 Diabetes (T2DM)
    Paul, Sanjoy K.
    Best, Jennie H.
    Khunti, Kamlesh
    Klein, Kerenaftali
    [J]. DIABETES, 2012, 61 : A363 - A363
  • [33] Vildagliptin is as effective as rosiglitazone in lowering HbA1c but without weight gain in drug-naive patients with type 2 diabetes (T2DM)
    Rosenstock, Julio
    Baron, Michelle A.
    Schweizer, Anja
    Mills, David
    Dejager, Sylvie
    [J]. DIABETES, 2006, 55 : A133 - A133
  • [34] Consistent Weight Changes Irrespective of Baseline HbA1c with the Combination of Empagliflozin/Linagliptin (EMPA/LINA) in Subjects with Type 2 Diabetes (T2DM)
    Barnett, Anthony H.
    Defronzo, Ralph A.
    Lewin, Andrew
    Patel, Sanjay
    Liu, Dacheng
    Kaste, Renee
    Broedl, Uli C.
    Lee, Christopher
    [J]. DIABETES, 2015, 64 : A656 - A656
  • [35] GLYCATED HEMOGLOBIN (HBA1C) CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) TREATED WITH CANAGLIFLOZIN IN A REAL-WORLD SETTING
    Lefebvre, P.
    Pilon, D.
    Robitaille, M.
    Lafeuille, M.
    Chow, W.
    Pfeifer, M.
    Duh, M. S.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A57 - A57
  • [36] Perception, HbA1c and the Quality of Life of Diabetes Mellitus (T2DM) Patients at RSUD Abdul Azis Singkawang
    Faridah, Imaniar Noor
    Masyithah, Nurul
    Perwitasari, Dyah Aryani
    [J]. ADVANCED SCIENCE LETTERS, 2017, 23 (12) : 12464 - 12468
  • [37] Long-Term Clinical Outcomes Associated With LDL-C and HbA1c Goal Achievement in Patients With Type 2 Diabetes Mellitus (T2DM)
    Shi, Lizheng
    Ye, Xin
    Lu, Mei
    Wu, Eric Q.
    Sharma, Hari
    Thomason, Darren
    Fonseca, Vivian
    [J]. DIABETES, 2013, 62 : A392 - A392
  • [38] Pharmacokinetics (PK) and Pharmacodynamics (PD) of PF-04991532, a Hepatoselective Glucokinase Activator (GKA), in T2DM Patients on Metformin Therapy
    Gustavson, Stephanie M.
    Pfefferkorn, Jeffrey A.
    Kazierad, David J.
    Chen, Danny
    Bergman, Arthur
    Wang, Xin
    Rolph, Timothy
    Rusnak, James M.
    [J]. DIABETES, 2013, 62 : A671 - A671
  • [39] Glycaemic control and pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
    Pang, W. H.
    Tan, Z.
    Todd, D.
    Halliday, M.
    Gill, F.
    Rhoads, M.
    Sathiskumar, P.
    Gallagher, A.
    de Chazal, R.
    Lawrence, I. G.
    [J]. DIABETIC MEDICINE, 2008, 25
  • [40] Identification of YH-GKA, a novel benzamide glucokinase activator as therapeutic candidate for type 2 diabetes mellitus
    Kaapjoo Park
    [J]. Archives of Pharmacal Research, 2012, 35 : 2029 - 2033
12345